However, the efficacy of anti-PD-1 antibody monotherapy is modest in r/r PTCL, with an ORR of 33-40%, and rapid disease progression poses a concern (11, 12). This evidence concerns the gene PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma.